US Representative
Dan Crenshaw Authored & Sponsored Legislation
Co-Sponsor of Legislation
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB3134
Introduced
5/1/25
Refer
5/1/25
Emergency Care Improvement Act
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB3179
Introduced
5/5/25
Refer
5/5/25
Refer
5/13/25
To rename the Anahuac National Wildlife Refuge located in the State of Texas as the "Jocelyn Nungaray National Wildlife Refuge".
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB318
Introduced
1/9/25
Refer
1/9/25
Refer
1/9/25
Border Safety and Security Act of 2025This bill requires the Department of Homeland Security (DHS) to suspend the entry of any non-U.S. nationals (aliens under federal law) without valid entry documents during any period when DHS cannot detain such an individual or return the individual to a foreign country contiguous to the United States. A state may sue DHS to enforce this requirement.(Under current law, non-U.S. nationals who arrive at the border without entry documents are generally subject to expedited removal. However, if such an individual is found to have a credible fear of persecution, they are typically subject to detention while their asylum claim is being considered.)The bill also authorizes DHS to suspend the entry of non-U.S. nationals without entry documents at the border if DHS determines that such a suspension is necessary to achieve operational control over such a border.
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB3205
Introduced
5/5/25
Refer
5/5/25
To deny tax deductions and other Federal funding for the costs of gender transition procedures.
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB327
Introduced
1/9/25
Refer
1/9/25
Valor Earned Not Stolen Act of 2025This bill increases the maximum prison term—from one year to three years—for an individual who falsely claims to be the recipient of certain military awards (e.g., a Medal of Honor or Purple Heart) with the intent to obtain money, property, or other tangible benefit.
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB3287
Introduced
5/8/25
Refer
5/8/25
Pregnancy.Gov Act
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB330
Introduced
1/9/25
Refer
1/9/25
Organ Donation Referral Improvement Act
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB3411
Introduced
5/14/25
Refer
5/14/25
Conscience Protection Act of 2025
Primary Sponsor of Legislation
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB339
Introduced
1/13/25
Refer
1/13/25
Broadband Resiliency and Flexible Investment Act
US
Us Congress 2025-2026 Regular Session
Us Congress House Bill HB340
Introduced
1/13/25
Refer
1/13/25
The HCT/P Modernization Act of 2025This bill requires the Food and Drug Administration (FDA) to provide information to stakeholders and report on the regulation of human cell and tissue products, also referred to as human cells, tissues, or cellular or tissue-based products (HCT/Ps), which are articles containing or consisting of human cells or tissues that are intended for use in a human recipient.The bill requires the FDA to conduct workshops to educate stakeholders and facilitate discussion with them on advancing the science and regulation of human cell and tissue products. The FDA must establish a public docket to receive written comments on this topic, and submit to Congress a report with recommendations on regulating these products. Additionally, the bill requires the FDA to publish on its website educational materials about the Tissue Reference Group and best practices for obtaining a recommendation about products from them. Also, annually for three years, the FDA must publish on its website information on the inquiries submitted and average response times for the Tissue Reference Group, as well as the number of human cell and tissue manufacturers that have registered with the FDA and the number of inspections the FDA has conducted with respect to these manufacturers since 2019. (The Tissue Reference Group is a working group within the FDA that receives product-specific questions from, and provides recommendations for, stakeholders on the regulation of human cell and tissue products under the FDA’s rules.)